Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients

dc.authoridYILMAZ, Mehmet/0000-0002-5710-5263
dc.authoridAkbulut, Sami/0000-0002-6864-7711
dc.authoridince, volkan/0000-0002-0714-490X
dc.authoridÖzgör, Dinçer/0000-0001-8519-8869
dc.authoridToprak, Hüseyin İlksen/0000-0001-9293-8116
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridKayaalp, Cuneyt/0000-0003-4657-2998
dc.authorwosidYilmaz, Mehmet/AAF-6095-2021
dc.authorwosidKayaalp, Cuneyt/AAH-1764-2021
dc.authorwosidYILMAZ, Mehmet/HKM-4739-2023
dc.authorwosidAkbulut, Sami/L-9568-2014
dc.authorwosidince, volkan/M-7325-2017
dc.authorwosidÖzgör, Dinçer/AAB-3523-2021
dc.authorwosidToprak, Hüseyin İlksen/AAN-4023-2020
dc.contributor.authorAkbulut, Sami
dc.contributor.authorKayaalp, Cuneyt
dc.contributor.authorYilmaz, Mehmet
dc.contributor.authorInce, Volkan
dc.contributor.authorOzgor, Dincer
dc.contributor.authorKarabulut, Koray
dc.contributor.authorEris, Cengiz
dc.date.accessioned2024-08-04T20:57:44Z
dc.date.available2024-08-04T20:57:44Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAIM: To investigate the therapeutic efficacy and safety of continuous autotransfusion system (CATS) during liver transplantation of hepatocellular carcinoma patients. METHODS: Eighty-three hepatocellular carcinoma (HCC) patients who underwent liver transplantation with intraoperative CATS (n = 24, CATS group) and without (n = 59, non-CATS group) between April 2006 and November 2011 at the Liver Transplant Institute of Inonu University were analyzed retrospectively. Postoperative HCC recurrence was monitored by measuring alpha-fetoprotein (AFP) levels at 3-mo intervals and performing imaging analysis by thoracoabdominal multidetector computed tomography at 6-month intervals. Inter-group differences in recurrence and correlations between demographic, clinical, and pathological data were assessed by ANOVA and chi(2) tests. Overall and disease-free survivals were calculated by the univariate Kaplan-Meier method. RESULTS: Of the 83 liver transplanted HCC patients, 89.2% were male and the overall mean age was 51.3 +/- 8.9 years (range: 18-69 years). The CATS and non-CATS groups showed no statistically significant differences in age, sex ratio, body mass index, underlying disease, donor type, graft-to-recipient weight ratio, Child-Pugh and Model for End-Stage Liver Disease scores, number of tumors, tumor size, AFP level, Milan and University of California San Francisco selection criteria, tumor differentiation, macrovascular invasion, median hospital stay, recurrence rate, recurrence site, or mortality rate. The mean follow-up time of the non-CATS group was 17.9 +/- 12.8 mo, during which systemic metastasis and/or locoregional recurrence developed in 25.4% of the patients. The mean follow-up time for the CATS group was 25.8 +/- 15.1 mo, during which systemic metastasis and/or locoregional recurrence was detected in 29.2% of the patients. There was no significant difference between the CATS and non-CATS groups in recurrence rate or site. Additionally, no significant differences existed between the groups in overall or disease-free survival. CONCLUSION: CATS is a safe procedure and may decrease the risk of tumor recurrence in HCC patients. (c) 2013 Baishideng. All rights reserved.en_US
dc.identifier.doi10.3748/wjg.v19.i10.1625
dc.identifier.endpage1631en_US
dc.identifier.issn1007-9327
dc.identifier.issue10en_US
dc.identifier.pmid23538988en_US
dc.identifier.startpage1625en_US
dc.identifier.urihttps://doi.org/10.3748/wjg.v19.i10.1625
dc.identifier.urihttps://hdl.handle.net/11616/102887
dc.identifier.volume19en_US
dc.identifier.wosWOS:000316060500016en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBaishideng Publ Grp Co Ltden_US
dc.relation.ispartofWorld Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLiver transplantationen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectIntraoperative blood salvage autotransfusionen_US
dc.subjectRecurrenceen_US
dc.subjectTumor cell disseminationen_US
dc.titleEffect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patientsen_US
dc.typeArticleen_US

Dosyalar